SAN JUAN CAPISTRANO, Calif., Jan. 10, 2007 (PRIME NEWSWIRE) -- American Mold Guard Inc. (Nasdaq:AMGI) through its wholly owned subsidiary, "AMG Scientific, LLC", announced today the release of an animated video demonstration of the company's novel Protection Plus interior surface treatment technology. The video illustrates AMG Scientific's Protection Plus(tm) technology developed to ebb the tide of hospital acquired infections (HAI). The animation shows the surface treatment covalently bonding to and combating numerous microbial attacks. AMG Scientific's Protection Plus(tm) treatment service aims to provide medical institutions and other organizations with an active defense against the spread of surface transmitted infectious disease. HAI's are a rampant problem that have escalated both morbidity and mortality rates as well as costing taxpayers millions of dollars.
The staggering economic impact of this problem was recently showcased on PBS's Nightly Business Report. Dr. Asif Ali, President of AMG Scientific was interviewed by reporter Jeff Yastine on December 28, 2006 in a segment entitled "Bill of Health" -- Infection Connection. In the segment, the Centers for Disease Control said roughly one in 10 hospitalized patients will acquire an infection after being admitted. That's about 1.7 million incidents annually resulting in the deaths of roughly 99,000 patients each year. Fueling concerns about HAI's was a November 2006 study by the Pennsylvania Health Care Cost Containment Council (PHC4). The unprecedented study, the first to quantify the number of these infections, found that patients with hospital-acquired infections were nearly six times as likely to die as other hospital patients who did not contract them. The primary cost is that patients with hospital-acquired infections have their stay prolonged, during which time they occupy scarce bed-days and require additional diagnostic and therapeutic interventions. Estimates of the cost of these infections in Pennsylvania alone were $3.5 billion annually and could approach $100 billion nationally. For many hospital infections, the costs of prevention are likely to be lower than the value of the resources released, even when costs are estimated liberally and the benefits presented conservatively. Under these circumstances, infection control should be pursued, since more stands to be gained than lost.
AMG Scientific's Protection Plus treatment service provides hospitals and other institutions with a surface intervention safety net to actively combat the spread of infectious diseases.
View Video -- "Protection Plus in Action":
http://www.redchip.com/visibility/investor.asp?symbol=AMGI&show=mediaRCAMGS or www.amgscientific.com.
For more information about AMG Scientific's Protection Plus service contact Dr. Asif Ali at 713-446-6768.
About American Mold Guard and AMG Scientific, LLC
American Mold Guard, Inc. (Nasdaq:AMGI), founded in 2002, is the industry leader in the field of surface treatment services. AMG Scientific, LLC is a wholly owned subsidiary of AMGI. Established in October 2006, AMG Scientific LLC, is focused on assisting hospitals, large organizations, institutions, military and government facility managers in combating the growing problem of interior surface treatment of infectious disease. Visit: www.amgscientific.com.
The American Mold Guard Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2964
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product and service development and market strategy. These statements may be identified by the fact that they use words or phrases such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue," "may," "could" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, competitive product and service development, future broad market acceptance of mold prevention and hospital acquired infection services, difficulties in raising additional capital in the future, difficulties and delays in establishing the "Mold Guard" brand, the impact of the absence of significant proprietary technology underlying our services, a continued and long-term dependence on a limited number of customers, changes to the inventory levels of the company's raw materials suppliers, the impact of a continued absence of exclusive or long-term commitments from the company's customers, changes in the anticipated size or trends of the markets in which the company competes, judicial decisions and governmental laws and regulations, and changes in general economic conditions in the markets in which the company may compete. For further details and a discussion of these and other risks and uncertainties, see the company's periodic reports including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, furnished to and filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.